Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

Dosage and Administration

Storage, reconstitution, and administration

Please refer to the full Prescribing Information for SHINGRIX for full details.

  • Refrigerate between 2º and 8ºC (36º and 46ºF). Protect vials from light. DO NOT FREEZE (discard if frozen)
  • Reconstitute and use immediately
  • Reconstituted vaccine is stable for 6 hours refrigerated between 2º and 8ºC (36º and 46ºF), and should be discarded after 6 hours. Do not freeze. Discard if the reconstituted vaccine has been frozen

Reconstituted Vaccine

VZV=varicella zoster virus; gE=glycoprotein E.

Reconstitution video

View reconstitution instructions for SHINGRIX.

Reference:

  1. Prescribing Information for SHINGRIX.

Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

  • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
  • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
  • Solicited local adverse reactions in subjects aged 50 years and older were pain (78.0%), redness (38.1%), and swelling (25.9%)
  • Solicited general adverse reactions in subjects aged 50 years and older were myalgia (44.7%), fatigue (44.5%), headache (37.7%), shivering (26.8%), fever (20.5%), and gastrointestinal symptoms (17.3%)
  • SHINGRIX was not studied in pregnant or lactating women, and it is unknown if it is excreted in human milk. Therefore, it cannot be established whether there is vaccine-associated risk with SHINGRIX in pregnant women or if there are effects on breastfed infants or milk production/excretion
  • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

All trademarks are the property of their respective owners.